ReviewCritical care (London, England)2010
Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread.
Review in Critical care (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02460588 (Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Article
- IPF-Acute Exacerbations: Advances and Future Perspectives.Frontiers in pharmacology · 2022Article
- Clinical Value of Bronchoscopy in Acute Respiratory Failure.Diagnostics (Basel, Switzerland) · 2021Review
- Long-term personal air pollution exposure and risk for acute exacerbation of idiopathic pulmonary fibrosis.Environmental health : a global access science source · 2021Article
- Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?American heart journal · 2020Review
- The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2019Review
- Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison.Respiratory research · 2019Article
- Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study.Journal of thoracic disease · 2019Article
- Non-intubated video-assisted thoracoscopic lung biopsy for interstitial lung disease: a single-center experience.Journal of thoracic disease · 2018Article
- Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.BMC pulmonary medicine · 2018Review
- Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?Critical care (London, England) · 2018Review
- Aerobic Exercise Protects from Pseudomonas aeruginosa-Induced Pneumonia in Elderly Mice.Journal of innate immunity · 2018Article
- The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.Frontiers in physiology · 2017Review
- Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.Respiratory medicine · 2016Article
- Article
- Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach.BMC pulmonary medicine · 2015Article
- Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.Stem cell reviews and reports · 2015Review
- Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.Journal of thoracic disease · 2015Review
- Article
- Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a dreadful, chronic, and irreversibly progressive fibrosing disease leading to death in all patients affected, and IPF acute exacerbations constitute the most devastating complication during its clinical course. IPF exacerbations are subacute/acute, clinically significant deteriorations of unidentifiable cause that usually transform the slow and more or less steady disease decline to the unexpected appearance of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) ending in death. The histological picture is that of diffuse alveolar damage (DAD), which is the tissue counterpart of ARDS, upon usual interstitial pneumonia, which is the tissue equivalent of IPF. ALI/ARDS and acute interstitial pneumonia share with IPF exacerbations the tissue damage pattern of DAD. 'Treatment' with high-dose corticosteroids with or without an immunosuppressant proved ineffective and represents the coup de grace for these patients. Provision of excellent supportive care and the search for and treatment of the 'underlying cause' remain the only options. IPF exacerbations require rapid decisions about when and whether to initiate mechanical support. Admission to an intensive care unit (ICU) is a particular clinical and ethical challenge because of the extremely poor outcome. Transplantation in the ICU setting often presents insurmountable difficulties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.